Citizens Maintains Market Outperform on OptimizeRx, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 93.3%

Neg 0% Neu 0% Pos 93.3%

Citizens analyst Constantine Davides maintains OptimizeRx (NASDAQ:OPRX) with a Market Outperform and raises the price target from $9 to $11.